Contrast MRA reduces cost for PVD diagnosis
The Veterans Affairs system could have saved more than $13 million in six years by using contrast-enhanced MR angiography instead of digital subtraction angiography for peripheral vascular disease imaging, according to a multicenter study presented at the 2006 International Society of Pharmacoeconomics and Outcomes Research meeting.
The Veterans Affairs system could have saved more than $13 million in six years by using contrast-enhanced MR angiography instead of digital subtraction angiography for peripheral vascular disease imaging, according to a multicenter study presented at the 2006 International Society of Pharmacoeconomics and Outcomes Research meeting.
J.W. Hay, Ph.D., an associate professor of pharmaceutical economics and policy at the University of Southern California, retrospectively reviewed VA outpatient data on almost 20,000 patients who underwent DSA and CE-MRA from 1999 to 2004. He found that use of CE-MRA reduced imaging costs by 55% over DSA. Costs per procedure were reduced by $950 compared with DSA.
Considering Breast- and Lesion-Level Assessments with Mammography AI: What New Research Reveals
June 27th 2025While there was a decline of AUC for mammography AI software from breast-level assessments to lesion-level evaluation, the authors of a new study, involving 1,200 women, found that AI offered over a seven percent higher AUC for lesion-level interpretation in comparison to unassisted expert readers.
SNMMI: Can 18F-Fluciclovine PET/CT Bolster Detection of PCa Recurrence in the Prostate Bed?
June 24th 2025In an ongoing prospective study of patients with biochemical recurrence of PCa and an initial negative PSMA PET/CT, preliminary findings revealed positive 18F-fluciclovine PET/CT scans in over 54 percent of the cohort, according to a recent poster presentation at the SNMMI conference.
